Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.91 |
| ▸ | MAPT | P10636 | 5/20 | 0.91 |
| ▸ | APP | P05067 | 5/20 | 0.91 |
| ▸ | LMNA | P02545 | 4/20 | 0.91 |
| ▸ | MEN1 | O00255 | 4/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.91 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | TP53 | P04637 | 2/20 | 0.86 |
| ▸ | MAOB | P27338 | 2/20 | 0.82 |
| ▸ | CTSL | P07711 | 1/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383218 | 1.00 | ABCG2 (0.91) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL5515061 | 1.00 | ABCG2 (0.91) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL25188859 | 0.97 | ABCG2 (0.97) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL30382670 | 0.95 | ABCG2 (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL30384538 | 0.95 | ABCG2 (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL634186 | 0.95 | ABCG2 (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL634187 | 0.95 | ABCG2 (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL25189208 | 0.95 | ABCG2 (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL25219780 | 0.93 | MAPT (1.00) | ABCG2MAPTAPPLMNAMEN1 | |
| SCHEMBL633177 | 0.93 | MAPT (1.00) | ABCG2MAPTAPPLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562803-B1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2025-10-15 | — | — | EP | claimed |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | claimed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | claimed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | claimed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | claimed |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | disclosed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | ABCG2 2354/4885MAPT 4067/4885APP 462/4885 |
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | ABCG2 806/4885MAPT 2256/4885APP 1333/4885 |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | ABCG2 2354/4885MAPT 4067/4885APP 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.